Oncogenes y Dianas Efectoras
PANCCUN
Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (10)
2023
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies
Advances in Cancer Research (Academic Press Inc.), pp. 367-413
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
2021
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376
-
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149
2020
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
2018
-
Cancertool: A visualization and representation interface to exploit cancer datasets
Cancer Research, Vol. 78, Núm. 21, pp. 6320-6328
2016
-
Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression
Oncogene, Vol. 35, Núm. 36, pp. 4719-4729